ClinicalTrials.gg
CompletedNCT01273857TICAPUpdated Nov 26, 2021Results posted

Transcoronary Infusion of Cardiac Progenitor Cells in Patients With Single Ventricle Physiology

A Phase 1 interventional study of Autologous cardiac progenitor cell transplantation and staged shunt procedure in Hypoplastic Left Heart Syndrome, Single Ventricle and Heart Failure, sponsored by Okayama University. Completed at 1 site in Japan. Open to participants aged Up to 6 Years. Per ClinicalTrials.gov, last updated 2021-11-26.

Sponsored by Okayama University · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Non-randomized
Ages
Up to 6 Years
Sex
All
01

Study summary

Hypoplastic left heart syndrome (HLHS) and related anomalies involved a single ventricle are characterized by hypoplasia of the left heart and the aorta with compromised systemic cardiac output. Infants with the syndrome generally undergo a staged surgical approach in view of an ultimate Fontan procedure. Although long-term survival in patients with HLHS and related single ventricle physiology has improved markedly with advances in medical and surgical therapies, a growing number of infants will ultimately require heart transplantation for end-stage heart failure due to several potential disadvantages include a negative effect on right ventricular function, arrhythmia, additional volume load via regurgitation from the nonvalved shunt, and impaired growth of the pulmonary artery.

Risk factors for poor outcome of heart transplantation with HLHS and single ventricle physiology are older age at transplantation and previous Fontan operation. New strategies are needed to improve the underlying transplant risks proper for the Fontan failure patients.

Emerging evidence suggests that heart-derived stem/progenitor cells can be used to improved cardiac function in patients with ischemic heart disease. In this trial, the investigators aimed to test the safety and feasibility of intracoronary injection of autologous cardiac progenitor cells in patients with HLHS and related single ventricle anomalies and that could improve ventricular function at 3 months' follow up.

Read the detailed description

Autologous cardiac progenitor cells are isolated from patients' own cardiac tissues obtained during palliative shunt procedure. Patients will receive 0.3 million/kg of autologous cardiac progenitor cells via intracoronary delivery 1 month after cardiac surgery. Follow-up visits 3 months to 1 year after cell injection will need to prospectively verify the clinical, laboratory, and safety-related data.

02

Conditions studied

  • Hypoplastic Left Heart Syndrome
  • Single Ventricle
  • Heart Failure

Keywords

  • Cardiac progenitor cells
  • Cell therapy
  • Hypoplastic Left Heart Syndrome
  • Single Ventricle
  • Norwood
  • Sano modification
  • Glenn
  • Fontan
03

In context

Hypoplastic Left Heart Syndrome

67 studies on the registry are indexed under Hypoplastic Left Heart Syndrome; 12 are open to participants now.

This study's enrollment of 14 is below the median of 30 across 41 interventional studies indexed under Hypoplastic Left Heart Syndrome.

Browse Hypoplastic Left Heart Syndrome studies →

Lead sponsor

Okayama University is the lead sponsor of 18 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 6 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Infants with hypoplastic left heart syndrome and related single ventricle anomalies undergoing first to third palliative shunt surgeries will be recruited into the study.
  • Patients between 0 and 6 years of age are eligible if written can be obtained.

Exclusion criteria

Exclusion Criteria:

  • Cardiogenic shock
  • Eisenmenger syndrome
  • Uncontrollable arrhythmia
  • Severe chronic diseases
  • Infections
  • Cancer
  • Unwillingness to participate
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Sham comparator
    Control

    Subjects will undergo standard staged-procedures without cell infusion

    Procedure: staged shunt procedure

  • Experimental
    Cell infusion

    Subjects will receive transcoronary infusion of autologous cardiosphere-derived cells 1 month after staged shunt procedure

    Procedure: Autologous cardiac progenitor cell transplantation · Procedure: staged shunt procedure

Interventions

  • ProcedureAutologous cardiac progenitor cell transplantation

    Patients will receive 0.3 million / kg of autologous cardiac progenitor cells via intracoronary delivery 1 month after cardiac surgery. Follow-up visits 3 months to 1 year after cell injection will need to prospectively verify the clinical, laboratory, and safety-related data.

    Also known as: Cardiosphere-derived cells

  • Procedurestaged shunt procedure

    Norwood-Glenn, Glenn, or Fontan procedure will be applied

06

What researchers measure

Primary outcomes

  1. Feasibility Evaluation and Major Cardiac Adverse Events Related to Transcoronary Infusion of Cardiac Progenitor Cells

    Feasibility was assessed by number of participants discontinued the study due to adverse events or number of participants received unsuccessful cell delivery by study physician. Unsuccessful was defined as failure of coronary selection of guiding catheter or direct cell infusion. The primary end point is to monitor major adverse cardiac events include death, sustained/symptomatic ventricular tachycardia, aggravation of heart failure, new myocardial infarction, unplanned cardiovascular operation for cardiac tamponade and infection in the first month after injection, and serially afterwards.

    Time frame: 3 months to 1 year after cell transplantation

Secondary outcomes

  1. Serious Adverse Events

    The incidence of hospitalization for heart failure, ventricular arrhythmia, general infection, and renal and hepatic dysfunction by CDC treatment.

    Time frame: 3 months to 1 year after cell transplantation

07

Results

Posted Jun 15, 2015

Participant flow

Participant flow — Overall Study
MilestoneControlCell Infusion
Started77
Completed77
Not completed00

Outcome measures

PrimaryFeasibility Evaluation and Major Cardiac Adverse Events Related to Transcoronary Infusion of Cardiac Progenitor Cells

Feasibility was assessed by number of participants discontinued the study due to adverse events or number of participants received unsuccessful cell delivery by study physician. Unsuccessful was defined as failure of coronary selection of guiding catheter or direct cell infusion. The primary end point is to monitor major adverse cardiac events include death, sustained/symptomatic ventricular tachycardia, aggravation of heart failure, new myocardial infarction, unplanned cardiovascular operation for cardiac tamponade and infection in the first month after injection, and serially afterwards.

Time frame:
3 months to 1 year after cell transplantation
Reported as:
Number · participants
Feasibility Evaluation and Major Cardiac Adverse Events Related to Transcoronary Infusion of Cardiac Progenitor Cells
participantsControlCell Infusion
Feasibility Evaluation and Major Cardiac Adverse Events Related to Transcoronary Infusion of Cardiac Progenitor Cells00
SecondarySerious Adverse Events

The incidence of hospitalization for heart failure, ventricular arrhythmia, general infection, and renal and hepatic dysfunction by CDC treatment.

Time frame:
3 months to 1 year after cell transplantation
Reported as:
Number · participants
Serious Adverse Events
participantsControlCell Infusion
Serious Adverse Events00

Adverse events

Collected over 1 years. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Control—0/7 (0%)0/7 (0%)
Cell Infusion—0/7 (0%)0/7 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)ControlCell InfusionTotal
Mean1.5 ± 1.72.1 ± 1.21.7 ± 1.5
Sex: Female, Male
Sex: Female, Male(Participants)ControlCell InfusionTotal
Female336
Male448
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)ControlCell InfusionTotal
Japanese7714
Region of Enrollment
Region of Enrollment(participants)ControlCell InfusionTotal
Japan7714
08

Study locations

1 site
  • Department of Regenerative Medicine, Center for Innovative Clinical Medicine, Okayama University Hospital
    Okayama, 700-8558, Japan
09

References and documents

Publications

  • Takehara N, Tsutsumi Y, Tateishi K, Ogata T, Tanaka H, Ueyama T, Takahashi T, Takamatsu T, Fukushima M, Komeda M, Yamagishi M, Yaku H, Tabata Y, Matsubara H, Oh H. Controlled delivery of basic fibroblast growth factor promotes human cardiosphere-derived cell engraftment to enhance cardiac repair for chronic myocardial infarction. J Am Coll Cardiol. 2008 Dec 2;52(23):1858-1865. doi: 10.1016/j.jacc.2008.06.052. PubMed 19038683 ↗
  • Tateishi K, Takehara N, Matsubara H, Oh H. Stemming heart failure with cardiac- or reprogrammed-stem cells. J Cell Mol Med. 2008 Dec;12(6A):2217-32. doi: 10.1111/j.1582-4934.2008.00487.x. Epub 2008 Aug 27. PubMed 18754813 ↗
  • Tateishi K, Ashihara E, Takehara N, Nomura T, Honsho S, Nakagami T, Morikawa S, Takahashi T, Ueyama T, Matsubara H, Oh H. Clonally amplified cardiac stem cells are regulated by Sca-1 signaling for efficient cardiovascular regeneration. J Cell Sci. 2007 May 15;120(Pt 10):1791-800. doi: 10.1242/jcs.006122. PubMed 17502484 ↗
  • Tateishi K, Ashihara E, Honsho S, Takehara N, Nomura T, Takahashi T, Ueyama T, Yamagishi M, Yaku H, Matsubara H, Oh H. Human cardiac stem cells exhibit mesenchymal features and are maintained through Akt/GSK-3beta signaling. Biochem Biophys Res Commun. 2007 Jan 19;352(3):635-41. doi: 10.1016/j.bbrc.2006.11.096. Epub 2006 Nov 27. PubMed 17150190 ↗
  • Ishigami S, Ohtsuki S, Tarui S, Ousaka D, Eitoku T, Kondo M, Okuyama M, Kobayashi J, Baba K, Arai S, Kawabata T, Yoshizumi K, Tateishi A, Kuroko Y, Iwasaki T, Sato S, Kasahara S, Sano S, Oh H. Intracoronary autologous cardiac progenitor cell transfer in patients with hypoplastic left heart syndrome: the TICAP prospective phase 1 controlled trial. Circ Res. 2015 Feb 13;116(4):653-64. doi: 10.1161/CIRCRESAHA.116.304671. Epub 2014 Nov 17. PubMed 25403163 ↗
  • Sano T, Ousaka D, Goto T, Ishigami S, Hirai K, Kasahara S, Ohtsuki S, Sano S, Oh H. Impact of Cardiac Progenitor Cells on Heart Failure and Survival in Single Ventricle Congenital Heart Disease. Circ Res. 2018 Mar 30;122(7):994-1005. doi: 10.1161/CIRCRESAHA.117.312311. Epub 2018 Jan 24. PubMed 29367212 ↗
  • Tarui S, Ishigami S, Ousaka D, Kasahara S, Ohtsuki S, Sano S, Oh H. Transcoronary infusion of cardiac progenitor cells in hypoplastic left heart syndrome: Three-year follow-up of the Transcoronary Infusion of Cardiac Progenitor Cells in Patients With Single-Ventricle Physiology (TICAP) trial. J Thorac Cardiovasc Surg. 2015 Nov;150(5):1198-1207, 1208.e1-2. doi: 10.1016/j.jtcvs.2015.06.076. Epub 2015 Jul 8. PubMed 26232942 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2011, a primary completion of Jan 2013 and a completion of Jan 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2015, 2 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2011
First posted
Jan 11, 2011
Start
Jan 2011
Primary completionActual
Jan 2013
CompletionActual
Jan 2013
Results first posted
Jun 15, 2015
Last update
Nov 26, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01273857
Lead sponsor
Okayama University
Collaborators
National Cerebral and Cardiovascular Center, Japan
Responsible party
Hidemasa Oh, MD (MD., Ph.D., Okayama University) — Principal investigator
First posted
Jan 11, 2011
Start date
Jan 2011
Primary completion
Jan 2013
Completion
Jan 2013
Results posted
Jun 15, 2015
Last update
Nov 26, 2021

Study contacts

Hidemasa Oh, M.D., Ph.D.
principal investigator · Department of Regenerative Medicine, Center for Innovative Clinical Medicine, Okayama University Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion